NASDAQ:INSYInsys Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Insys Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.29 0.00 (0.00 %) (As of 03/20/2020) Add Compare Share Today's Range$0.29Now: $0.29▼$0.2950-Day Range$0.23MA: $23,687,640.18▼$65,799,000.0052-Week Range$0.14Now: $0.29▼$11.65VolumeN/AAverage Volume9.52 million shsMarket Capitalization$21.71 millionP/E RatioN/ADividend YieldN/ABeta3.21 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Insys Therapeutics. Previous Next 2.7 Community Rank Outperform VotesInsys Therapeutics has received 449 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInsys Therapeutics has received 372 “underperform” votes. (Add your “underperform” vote.)Community SentimentInsys Therapeutics has received 54.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote “Outperform” if you believe INSY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInsys Therapeutics does not currently pay a dividend.Dividend GrowthInsys Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insys Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders65.40% of the stock of Insys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.93% of the stock of Insys Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insys Therapeutics are expected to grow in the coming year, from ($1.55) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insys Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insys Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.87 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INSY Previous SymbolNASDAQ:NEOL CUSIPN/A CIK1516479 Webwww.insysrx.com Phone480-500-3127Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.50Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$82.08 million Price / Sales0.26 Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-0.50Profitability EPS (Most Recent Fiscal Year)($1.39) Net Income$-124,510,000.00 Net Margins-346.61% Return on Equity-1,430.37% Return on Assets-64.04%Miscellaneous Employees226 Outstanding Shares74,570,000Market Cap$21.71 million Next Earnings DateN/A OptionableOptionable Receive INSY News and Ratings via Email Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter. Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions How were Insys Therapeutics' earnings last quarter? Insys Therapeutics Inc (NASDAQ:INSY) posted its earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.33. The specialty pharmaceutical company earned $7.63 million during the quarter, compared to analyst estimates of $14.95 million. Insys Therapeutics had a negative net margin of 346.61% and a negative return on equity of 1,430.37%. The firm's revenue was down 68.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.19) earnings per share. View Insys Therapeutics' earnings history. When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work? Insys Therapeutics shares split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were issued to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split. Has Insys Therapeutics been receiving favorable news coverage? Media stories about INSY stock have trended negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insys Therapeutics earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutInsys Therapeutics. Who are some of Insys Therapeutics' key competitors? Some companies that are related to Insys Therapeutics include Oncolytics Biotech (ONCY), Otonomy (OTIC), Sesen Bio (SESN), Clearside Biomedical (CLSD), Onconova Therapeutics (ONTX), CV Sciences (CVSI), Monopar Therapeutics (MNPR), CTI BioPharma (CTIC), Celsion (CLSN), Synlogic (SYBX), SCYNEXIS (SCYX), Assertio Therapeutics (ASRT), Bellerophon Therapeutics (BLPH), Oramed Pharmaceuticals (ORMP) and ContraFect (CFRX). View all competitors. What other stocks do shareholders of Insys Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insys Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Medivation (MDVN) and NVIDIA (NVDA). Who are Insys Therapeutics' key executives? Insys Therapeutics' management team includes the following people: Mr. Steven J. Meyer, Exec. Chairman (Age 62)Mr. Saeed Motahari, CEO, Pres & Director (Age 53)Mr. Andrew G. Long, Chief Financial OfficerDr. Danny L. Tuck, Sr. VP of Quality OperationsMr. Franc Del Fosse, Sr. VP of Corp. Affairs (Age 47) What is Insys Therapeutics' stock symbol? Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY." What is Insys Therapeutics' stock price today? One share of INSY stock can currently be purchased for approximately $0.29. How big of a company is Insys Therapeutics? Insys Therapeutics has a market capitalization of $21.71 million and generates $82.08 million in revenue each year. The specialty pharmaceutical company earns $-124,510,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Insys Therapeutics employs 226 workers across the globe. What is Insys Therapeutics' official website? The official website for Insys Therapeutics is www.insysrx.com. How can I contact Insys Therapeutics? Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected] This page was last updated on 6/4/2020 by MarketBeat.com Staff
